25 October 2010

(“Sareum” or the “Company”)

Sareum to Present at Major Research Congress in China

Sareum (AIM: SAR), the specialist cancer drug discovery business, is pleased to announce that Dr Tim Mitchell, CEO, and Dr John Reader, CSO, will present Sareum’s cancer research programmes and SKIL drug discovery platform at the 8th International Drug Discovery Sciences and Technology (IDDST) Congress in Beijing, China.

Today, Dr Mitchell will present Sareum’s SKIL platform at the session focussing on new kinase inhibitors. Tomorrow (Oct 26), Dr Reader will present Sareum’s Chk-1 and VEGFR-3 cancer research programmes at the symposium dedicated to cancer drug discovery.

Sareum’s CEO, Dr Tim Mitchell, commented: “China is set to become one of the major forces in bio-science innovation. This is a significant opportunity for us to showcase our drug research programmes and the technology behind them at this prestigious congress, as well as at the many company meetings that will take place after the event.

Sareum Holdings plc


Tim Mitchell

01223 497 700

Merchant Securities Limited (Nomad)

Simon Clements/Bidhi Bhoma

020 7628 2200

Hybridan LLP (Broker)


Claire Noyce

020 7947 4350

Notes for editors:

About Sareum Holdings plc

Sareum is a drug discovery company, headquartered in Cambridge UK, that is focused on producing targeted small molecule therapeutics to address unmet medical needs, primarily in cancer. Sareum aims to successfully deliver drug candidates for licensing to pharmaceutical and biotechnology companies at the pre-clinical or early clinical trials stage.

Sareum’s Chk1 kinase cancer research programme is a joint research collaboration with The Institute of Cancer Research and Cancer Research Technology Limited. Novel chemical compounds developed by the collaboration have been shown to increase the effectiveness of current cancer therapeutics in in-vivo cancer models.

SKIL® (Sareum Kinase Inhibitor Library) is Sareum’s drug discovery technology platform that has so far produced the Company’s Aurora, VEGFR-3, FLT3 & TYK2 kinase cancer and auto-immune disease research programmes. SKIL can also generate drug research programmes against other kinase targets.

Sareum Holdings plc joined the AIM market of the London Stock Exchange in October 2004, trading under the symbol SAR.  For further information, please visit www.sareum.co.uk